Oramed Pharmaceuticals (ORMP): Shareholder Letter Spurs Bullish Trend
After releasing a letter to shareholders, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares has seen a significant increase on the US stock charts. As of the latest current-market check, ORMP stock price increased 18.82% to $2.66. Program For Stock Repurchases And Strategic Update Nadav Kidron, the CEO of Oramed Pharmaceuticals (ORMP), sent a detailed letter to ...
Express News | Oramed Pharmaceuticals Shares Are Trading Higher After the Company Announced a $20 Million Buyback Program and Finalized Its Joint Venture With Hefei Tianhui Biotech
Express News | Oramed Pharmaceuticals And Hefei Tianhui Biotech Finalize Joint Venture; JV To Receive Capital Infusion With HTIT Committing $70M In Cash And Oramed Investing $25M In Cash and Stock
Express News | Oramed Pharmaceuticals: Htit Committing $70 Mln in Cash, Co Investing $25 Mln in Cash & Stock in Jv
Express News | Oramed Pharmaceuticals Inc: Jv With Chinese Partner, Htit
Express News | Oramed Pharmaceuticals Authorizes $20M Buyback
Express News | Oramed Pharmaceuticals - Authorized Common Stock Repurchase Plan Allowing for Buy-Back of up to $20 Mln in Maximum Value of Its Common Stock
Express News | Oramed Pharmaceuticals Inc. Announces the Buy-Back of Its Common Stock
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersAvidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. Molecular Partners (NASDAQ:MOLN) shares moved
Scilex Holding Signs Commitment Letter for $100 Million Financing
Scilex Holding (SCLX) said Tuesday that it signed a commitment letter with Perigrove and Graf Holdings as lenders for a $100 million, five-year term financing with royalty-based payments.
Express News | Oramed Pharmaceuticals Inc - on June 6, Appointed Avraham Gabay to Serve as CFO, Treasurer and Secretary
HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oramed Pharmaceuticals (NASDAQ:ORMP) with a Neutral.
Oramed Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/20/2024 — HC Wainwright & Co. Reiterates → Neutral 05/17/2023 -12.28% Canaccord Genuity $3 → $2 Mainta
Express News | Compugen Appoints David Silberman As Its New CFO Effective August 15, 2024, Taking Over From Alberto Sessa Who Will Depart On The Same Day
Oramed Pharmaceuticals Seeks New CFO After Resignation
Express News | Oramed Pharmaceuticals Inc - on May 10, David Silberman, Co's CFO Resigned From His Positions With Company
Oramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (Vs US$0.085 Loss in 1Q 2023)
Oramed Pharmaceuticals | 10-Q: Quarterly report
Express News | Oramed Pharmaceuticals Inc - on May 2, Received Additional Payment of About $9.6 Mln Pursuant to Terms of Note
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More